Frances Anastassacos
Co-Founder Nabla Bio, Inc.
Frances is a cofounder at Nabla Bio, an AI-native biotech company that uses generative protein design and multiplexed experimentation to create precise therapeutic antibodies against challenging targets, including GPCRs. At Nabla, she works at the interface of AI and experimentation, integrating large-scale AI models with wet-lab platforms to design highly selective, developable biologics. Frances completed her PhD in Biological and Biomedical Sciences at Harvard University and holds a master’s degree in Chemistry from the University of St Andrews.
Seminars
Tuesday 28th April 2026
Transforming the Development of Functional Anti-GPCR Antibodies with AI-Driven Design
9:00 am
- Leveraging AI-driven design antibodies against GPCRs without immunization or display, including targeting deep intra-pocket epitopes previously inaccessible to conventional methods
- Generating large panels of GPCR-binding antibodies in a single computational run, achieving high hit rates and experimentally light workflows that validate both binding and functional activity in high relevance settings
- Demonstrating AI-enabled functional design, including agonism, antagonism, and ligand-mimicking behaviours, and highlighting why this represents a step-change for GPCR drug discovery
Tuesday 28th April 2026
Panel Discussion: From Static Pictures to Intelligent Pipelines – The Next Era of AI-Driven GPCR Discovery
11:15 am
- How can dynamic modeling, data integration, and cross-disciplinary collaboration be connected to create a truly cohesive GPCR discovery ecosystem?
- What operational barriers must be overcome to achieve genuine AI-enabled translational science across academia and industry?
- What does the roadmap look like for structure-guided and AI-assisted GPCR discovery to reshape drug development over the next decade?
Tuesday 28th April 2026
Chair’s Opening Remarks
8:45 am
Tuesday 28th April 2026
Chair’s Closing Remarks
3:15 pm
